Ruth Perets

10PUBLICATIONS
85CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Apr 21, 2026
CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3.

|Apr 09, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Amaury Daste, Xiuning Le, Amani Makkouk

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

Pageof 2

Frequent Collaborators

2 joint publications

Byoung Chul Cho

2 joint publications

Stephane Champiat

1 joint publications

Yuval Tabach

1 joint publications

Eyal Gottlieb